search
Back to results

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

Primary Purpose

Uterine Sarcoma

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Everolimus
Sponsored by
The University of Texas Health Science Center at San Antonio
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Uterine Sarcoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)Female

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    April 2, 2018
    Last Updated
    August 25, 2022
    Sponsor
    The University of Texas Health Science Center at San Antonio
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03493165
    Brief Title
    Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
    Official Title
    Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    August 2022
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    The University of Texas Health Science Center at San Antonio

    4. Oversight

    5. Study Description

    Brief Summary
    Single patient treatment with everolimus.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Uterine Sarcoma

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Everolimus
    Other Intervention Name(s)
    Zortress, Afinitor, and Afinitor Disperz
    Intervention Description
    mTOR inhibitor

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    John Sarantopoulos, MD
    Phone
    210-450-1785
    Email
    sarantopoulo@uthscsa.edu

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

    We'll reach out to this number within 24 hrs